The field of obesity pharmacotherapy is advancing at an accelerated pace, with exciting new successively potent drug trials showing promise in treating obesity and its related complications. This succinct session will highlight the latest advancements in 3rd (and 4th) generation anti-obesity treatments and novel lines of query and modes of action that have multiple downstream target effects. A brief mention of the efficacy of these treatments and their related CV data and benefits in other disease states (OSA, OA, MAFLD and neurological disease) will be discussed.